SB132 Alabama 2025 Session

Summary

Primary Sponsor

Tim MelsonSenator

Republican

Session

2025 Regular Session

Title

Controlled substances; psychoactive derivatives of hemp added as Schedule I drug

Summary

SB132 would place psychoactive hemp-derived cannabinoids on Schedule I and repeal the ban on selling them to minors.

What This Bill Does

The bill makes only non-psychoactive cannabinoids derived from hemp exempt from Schedule I, while classifying psychoactive cannabinoids (like Delta-8, Delta-9, and Delta-10) as Schedule I controlled substances. It also repeals the provision that prohibits selling psychoactive cannabinoids to minors. Additionally, it introduces a framework for identifying and scheduling synthetic controlled substance analogues and requires relevant state agencies to coordinate on scheduling. The act becomes effective on October 1, 2025.

Who It Affects

• Businesses that manufacture, distribute, or sell hemp-derived cannabinoids—especially psychoactive ones—will be subject to Schedule I controls and associated regulatory changes.
• Minors and the general public would be affected by the removal of the specific prohibition on selling psychoactive cannabinoids to minors (though these substances would be controlled under Schedule I).

Key Provisions

• Non-psychoactive hemp cannabinoids remain exempt from Schedule I, but psychoactive cannabinoids from hemp are added to Schedule I.
• Repeals Section 13A-12-214.4, removing the prohibition on selling psychoactive cannabinoids to minors.
• Establishes a framework for identifying and classifying synthetic controlled substance analogues as Schedule I and requires the Alabama Department of Forensic Sciences to notify the Department of Public Health when classification occurs.
• Effective date: October 1, 2025.

AI-generated summary using openai/gpt-5-nano on Feb 22, 2026. May contain errors — refer to the official bill text for accuracy.

Subjects

Crimes & Offenses